Eye News and Research

Latest Eye News and Research

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Many drug-resistant infections are the result of bacterial biofilms, structured aggregates of bacteria that live on surfaces and that are extremely resistant to environmental stresses. These biofilms impact human health in many ways - cystic fibrosis, for example, is a disease in which patients die from airway bacterial biofilm infections that are invulnerable to even the most potent antibiotics.

11 Oct 2010

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).

11 Oct 2010

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Just as intense concentration allows a sharp mind to perform at its peak, a research institute that concentrates pre-eminent scientists from 11 academic departments can push back the frontiers of knowledge in a complex research area: the human brain.

8 Oct 2010

Intestinal bacteria send signals that promote cell proliferation in Wnt signaling pathway

Microbes matter -- perhaps more than anyone realizes -- in basic biological development and, maybe, they could be a target for reducing cancer risks, according to University of Oregon researchers.

8 Oct 2010

Scientists develop first screening method to identify river blindness disease

Scientists from The Scripps Research Institute have developed the first screening method that rapidly identifies individuals with active river blindness, a parasitic disease that afflicts an estimated 37 million people. The test could change the current strategy of mass treatment in areas where river blindness, also known as onchocerciasis, is suspected.

7 Oct 2010

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.

7 Oct 2010

ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray

ISTA Pharmaceuticals, Inc., today announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray conducted in Canada for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies.

6 Oct 2010

Gentel Biosciences, RayBiotech to develop antibody array products with APiX chromogenic detection platform

Gentel Biosciences, a leader in proteomics profiling tools and RayBiotech, Inc., a pioneer and leader in protein and antibody array technologies, jointly announce today their partnership to develop and market RayBiotech's vast collection of antibody array products covering a wide variety of cytokines and other proteins for use with Gentel's APiX chromogenic detection platform.

5 Oct 2010

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).

4 Oct 2010

Cost-effective ways for early detection of 'lazy eye'

Amblyopia, known as "lazy eye," is a major cause of vision problems in children and a common cause of blindness in people aged 20 to 70 in developed countries. In amblyopia the person's stronger eye is favored and his/her weaker eye gradually loses visual power as a result. When the condition is detected and treated before age 7, more than 75 percent of children achieve 20/30 vision or better, the Amblyopia Treatment Study reports.

4 Oct 2010

New edition of Sturge-Weber Syndrome textbook published

Eleven years after the first edition, a new edition of the Sturge-Weber Syndrome textbook has been published by the Sturge-Weber Foundation in New Jersey. Co-author E. Steve Roach, MD, is chief of Neurology and vice-chair of Pediatrics at Nationwide Children's Hospital.

4 Oct 2010

Study shows no difference between Bevacizumab and Ranibizumab efficacy in treating AMD

Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

4 Oct 2010

Study shows low DRC level may increase risk for non-melanoma skin cancer

DNA repair capacity (DRC) measurements effectively identified individuals who were at high risk for non-melanoma skin cancer, and may be a useful method to evaluate the efficacy of preventive therapies, according to study results presented at the Third AACR Conference on the Science of Cancer Health Disparities.

3 Oct 2010

Feeding infants before examination for retinopathy of prematurity reduces stress

Premature infants are often examined for retinopathy of prematurity (ROP). This exam can be quite stressful for the neonate, causing changes in heart rate, blood pressure and oxygen saturation, and increased crying. In a recent study published in the Journal of AAPOS, the Official Publication of the American Association of Pediatric Ophthalmology and Strabismus, researchers found that feeding infants one hour before the examination unexpectedly reduced stress but did not increase vomiting or gastric aspirates.

30 Sep 2010

ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has signed a 10-year supply agreement with MSD Biologics (UK) Ltd, part of the Merck BioManufacturing Network, for the production of microplasmin. ThromboGenics anticipates that this deal will meet its long-term commercial needs for bulk drug substance of this novel therapeutic agent.

30 Sep 2010

Researchers receive NIH award to investigate regenerative potential of retinal cells

Zhang and co-principal investigators Sheng Ding, PhD, from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells. Their long-term goal is to restore visual function lost through diseases such as macular degeneration and retinitis pigmentosa.

30 Sep 2010

FDA clears Abbott's RevitaLens Ocutec contact lens disinfecting solution

Abbott has received U.S. Food and Drug Administration (FDA) market clearance for RevitaLens Ocutec™, a unique next-generation multi-purpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.

30 Sep 2010

Researchers identify gene activator that allows stem cells to transform any type of cell

Emerging Healthcare Solutions, Inc. was energized Monday by news that researchers in North Carolina may have identified the gene activator that allows stem cells to reproduce and become any type of cell in the body.

29 Sep 2010

Study finds ultrafine air particulates exposure may increase risk of heart disease in firefighters

Firefighters are exposed to potentially dangerous levels of ultrafine particulates at the time they are least likely to wear protective breathing equipment. Because of this, researchers believe firefighters may face an increased risk for heart disease from exposures during the fire suppression process.

29 Sep 2010

Text: The Republican 'Pledge' on health care

With an eye on the midterm elections, Republicans in the House of Representative released "A Pledge to America" -- an outline of what they plan to do if they gain control of Congress.

29 Sep 2010

Eye News and Research

Latest Eye News and Research

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Intestinal bacteria send signals that promote cell proliferation in Wnt signaling pathway

Scientists develop first screening method to identify river blindness disease

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray

Gentel Biosciences, RayBiotech to develop antibody array products with APiX chromogenic detection platform

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Cost-effective ways for early detection of 'lazy eye'

New edition of Sturge-Weber Syndrome textbook published

Study shows no difference between Bevacizumab and Ranibizumab efficacy in treating AMD

Study shows low DRC level may increase risk for non-melanoma skin cancer

Feeding infants before examination for retinopathy of prematurity reduces stress

ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin

Researchers receive NIH award to investigate regenerative potential of retinal cells

FDA clears Abbott's RevitaLens Ocutec contact lens disinfecting solution

Researchers identify gene activator that allows stem cells to transform any type of cell

Study finds ultrafine air particulates exposure may increase risk of heart disease in firefighters

Text: The Republican 'Pledge' on health care

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye News and Research

Latest Eye News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in